The stock of Genprex Inc (NASDAQ: GNPX) has decreased by -4.82 when compared to last closing price of 0.28. Despite this, the company has experienced a 11.78% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-07 that Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education AUSTIN, Texas, May 7, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored Research Agreement (SRA) with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt) to study Type 1 diabetes (T1D) and Type 2 diabetes (T2D), the parties have entered into a new SRA to study GPX-002, the Company’s gene therapy for diabetes, in T1D and T2D in animal models. “We continue to make advancements in our studies of GPX-002 in both T1D and T2D, including mouse models, construct optimization and studies in other animal models,” said Ryan Confer, President and Chief Executive Officer at Genprex.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
The 36-month beta value for GNPX is also noteworthy at -0.47. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GNPX is 27.06M, and at present, short sellers hold a 9.46% of that float. The average trading volume of GNPX on May 22, 2025 was 4.50M shares.
GNPX’s Market Performance
GNPX stock saw an increase of 11.78% in the past week, with a monthly gain of 13.85% and a quarterly increase of -32.66%. The volatility ratio for the week is 11.79%, and the volatility levels for the last 30 days are 12.98% for Genprex Inc (GNPX). The simple moving average for the past 20 days is -4.33% for GNPX’s stock, with a -62.70% simple moving average for the past 200 days.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at -10.12% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.53% of loss for the given period.
Volatility was left at 12.98%, however, over the last 30 days, the volatility rate increased by 11.79%, as shares sank -0.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.93% lower at present.
During the last 5 trading sessions, GNPX rose by +12.29%, which changed the moving average for the period of 200-days by -81.91% in comparison to the 20-day moving average, which settled at $0.2767. In addition, Genprex Inc saw -68.92% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -1530.6 for the present operating margin
- -0.23 for the gross margin
The net margin for Genprex Inc stands at -1926.88. The total capital return value is set at -3.92. Equity return is now at value -302.69, with -205.73 for asset returns.
Currently, EBITDA for the company is -21.1 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 390.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.94.
Conclusion
In summary, Genprex Inc (GNPX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
